Catalyst Biosciences Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering of Common Stock
February 11, 2021 16:01 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced that in connection with its previously announced public...
Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress
February 03, 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – MarzAA,...
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
January 29, 2021 16:01 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,000...
Catalyst Biosciences Announces Pricing of Public Offering of Common Stock
January 27, 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO (the “Company”) today announced the pricing of an underwritten public offering of 8,700,000...
Catalyst Biosciences Announces Proposed Public Offering of Common Stock
January 26, 2021 16:04 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten public...
Catalyst Biosciences Announces Poster Presentations at the EAHAD 2021 Virtual Congress
January 20, 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and...
Catalyst Biosciences Participating in a Fireside Chat with LifeSci Capital
January 15, 2021 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat...
Catalyst Biosciences Presents Crimson 1 Phase 3 Study Design at the 62nd Annual American Society of Hematology Conference
December 07, 2020 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting,...
Catalyst Biosciences Hosting Research & Development Call on Systemic Complement Regulator Programs
December 03, 2020 16:02 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company’s systemic...
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors
December 02, 2020 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...